← FDA DRUG APPROVALS

FDA NDA · NDA219839

ZEGFROVY

Sponsor: DIZAL

APPLICATION
NDA219839
TYPE
NDA
ORIGINAL APPROVAL
2025-07-02
LATEST ACTION
2025-07-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ZEGFROVY · ReferencePrescription
SUNVOZERTINIB 200MG · TABLET · ORAL
ZEGFROVY · ReferencePrescription
SUNVOZERTINIB 150MG · TABLET · ORAL

Approval history

2025-07-02Type 1 - New Molecular Entity · Original · priorityLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →